Advertisement

Analytical and Bioanalytical Chemistry

, Volume 410, Issue 16, pp 3847–3857 | Cite as

Biomimetic trapping cocktail to screen reactive metabolites: use of an amino acid and DNA motif mixture as light/heavy isotope pairs differing in mass shift

  • Shuto Hosaka
  • Takuto Honda
  • Seon Hwa Lee
  • Tomoyuki Oe
Research Paper

Abstract

Candidate drugs that can be metabolically transformed into reactive electrophilic products, such as epoxides, quinones, and nitroso compounds, are of special concern because subsequent covalent binding to bio-macromolecules can cause adverse drug reactions, such as allergic reactions, hepatotoxicity, and genotoxicity. Several strategies have been reported for screening reactive metabolites, such as a covalent binding assay with radioisotope-labeled drugs and a trapping method followed by LC–MS/MS analyses. Of these, a trapping method using glutathione is the most common, especially at the early stage of drug development. However, the cysteine of glutathione is not the only nucleophilic site in vivo; lysine, histidine, arginine, and DNA bases are also nucleophilic. Indeed, the glutathione trapping method tends to overlook several types of reactive metabolites, such as aldehydes, acylglucuronides, and nitroso compounds. Here, we introduce an alternate way for screening reactive metabolites as follows: A mixture of the light and heavy isotopes of simplified amino acid motifs and a DNA motif is used as a biomimetic trapping cocktail. This mixture consists of [2H0]/[2H3]-1-methylguanidine (arginine motif, Δ 3 Da), [2H0]/[2H4]-2-mercaptoethanol (cysteine motif, Δ 4 Da), [2H0]/[2H5]-4-methylimidazole (histidine motif, Δ 5 Da), [2H0]/[2H9]-n-butylamine (lysine motif, Δ 9 Da), and [13C0,15N0]/[13C1,15N2]-2′-deoxyguanosine (DNA motif, Δ 3 Da). Mass tag triggered data-dependent acquisition is used to find the characteristic doublet peaks, followed by specific identification of the light isotope peak using MS/MS. Forty-two model drugs were examined using an in vitro microsome experiment to validate the strategy.

Graphical abstract

Biomimetic trapping cocktail to screen reactive metabolites

Keywords

Mass spectrometry Activated drug Trapping reagent Cocktail reagent 

Notes

Acknowledgements

This work was supported in part by a Grant-in-Aid for Challenging Exploratory Research (to T.O., no. 25670008 for 2013–2014) from Japan Society for the Promotion of Science (JSPS) and TaNeDS 2014 (to T.O., for 2014–2017) from Daiichi Sankyo Co., Ltd. The authors thank Astellas Pharma Inc. (Tsukuba, Japan) for donating a used LCQ DECA. The authors also thank Mr. Reona Yoshiizumi of our laboratory for help in preparing KP-NHS.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Supplementary material

216_2018_1057_MOESM1_ESM.pdf (658 kb)
ESM 1 (PDF 657 kb)

References

  1. 1.
    Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov. 2011;10:292–306.  https://doi.org/10.1038/nrd3408.CrossRefPubMedGoogle Scholar
  2. 2.
    Bu HZ, Kang P, Deese AJ, Zhao P, Pool WF. Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos. 2005;33:1920–4.  https://doi.org/10.1124/dmd.105.006866.CrossRefPubMedGoogle Scholar
  3. 3.
    Albano E, Rundgren M, Harvison PJ, Nelson SD, Moldéus P. Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity. Mol Pharmacol. 1985;28:306–311. doi: not available (http://molpharm.aspetjournals.org/content/28/3/306).
  4. 4.
    Callan HE, Jenkins RE, Maggs JL, Lavergne SN, Clarke SE, Naisbitt DJ, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol. 2009;22:937–48.  https://doi.org/10.1021/tx900034r.CrossRefPubMedGoogle Scholar
  5. 5.
    Srivastava A, Maggs JL, Antoine DJ, Williams DP, Smith DA, Park BK. Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol. 2010;196:165–194. doi: not available (ISBN: 978–3–642-00662-3, Print, 978-3-642-00663-0, Online).Google Scholar
  6. 6.
    Chen X, Tharmanathan T, Mannargudi B, Gou H, Uetrecht JP. A study of the specificity of lymphocytes in nevirapine-induced skin rash. J Pharmacol Exp Ther. 2009;331:836–41.  https://doi.org/10.1124/jpet.109.157362.CrossRefPubMedGoogle Scholar
  7. 7.
    Chipinda I, Hettick JM, Siegel PD. Haptenation: chemical reactivity and protein binding. J Allergy. 2011;2011:1–11.  https://doi.org/10.1155/2011/839682.CrossRefGoogle Scholar
  8. 8.
    Baer BR, Wienkers LC, Rock DA. Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol. 2007;20:954–64.  https://doi.org/10.1021/tx700037e.CrossRefPubMedGoogle Scholar
  9. 9.
    Sridar C, Kenaan C, Hollenberg PF. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Dispos. 2012;40:2256–66.  https://doi.org/10.1124/dmd.112.046979.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Henne KR, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, et al. Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. Drug Metab Dispos. 2012;40:1429–40.  https://doi.org/10.1124/dmd.112.045708.CrossRefPubMedGoogle Scholar
  11. 11.
    Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, et al. Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation. Drug Metab Dispos. 2007;35:848–58.  https://doi.org/10.1124/dmd.106.013649.CrossRefPubMedGoogle Scholar
  12. 12.
    Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, Beconi MG. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Methods. 2005;52:278–85.  https://doi.org/10.1016/j.vascn.2004.11.006.CrossRefPubMedGoogle Scholar
  13. 13.
    Prakash C, Sharma R, Gleave M, Nedderman A. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr Drug Metab. 2008;9:952–64.  https://doi.org/10.2174/138920008786485209.CrossRefPubMedGoogle Scholar
  14. 14.
    Yan Z, Maher N, Torres R, Caldwell GW, Huebert N. Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19:3322–30.  https://doi.org/10.1002/rcm.2195.CrossRefPubMedGoogle Scholar
  15. 15.
    Mutlib A, Lam W, Atherton J, Chen H, Galatsis P, Stolle W. Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites. Rapid Commun Mass Spectrom. 2005;19:3482–92.  https://doi.org/10.1002/rcm.2223.CrossRefPubMedGoogle Scholar
  16. 16.
    Yan Z, Caldwell GW, Maher N. Unbiased high-throughput screening of reactive metabolites on the linear ion trap mass spectrometer using polarity switch and mass tag triggered data-dependent acquisition. Anal Chem. 2008;80:6410–22.  https://doi.org/10.1021/ac800887h.CrossRefPubMedGoogle Scholar
  17. 17.
    Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu CP, et al. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol. 2005;18:1537–44.  https://doi.org/10.1021/tx0501637.CrossRefPubMedGoogle Scholar
  18. 18.
    Yan Z, Maher N, Torres R, Huebert N. Use of a trapping agent for simultaneous capturing and high-throughput screening of both “soft” and “hard” reactive metabolites. Anal Chem. 2007;79:4206–14.  https://doi.org/10.1021/ac0701029.CrossRefPubMedGoogle Scholar
  19. 19.
    Laine JE, Auriola S, Pasanen M, Juvonen RO. d-isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. Toxicol in Vitro. 2011;25:411–25.  https://doi.org/10.1016/j.tiv.2010.11.002.CrossRefPubMedGoogle Scholar
  20. 20.
    Damsten MC, Commandeur JN, Fidder A, Hulst AG, Touw D, Noort D, et al. Liquid chromatography/tandem mass spectrometry detection of covalent binding of acetaminophen to human serum albumin. Drug Metab Dispos. 2007;35:1408–17.  https://doi.org/10.1124/dmd.106.014233.CrossRefPubMedGoogle Scholar
  21. 21.
    Antunes AM, Godinho AL, Martins IL, Oliveira MC, Gomes RA, Coelho AV, et al. Protein adducts as prospective biomarkers of nevirapine toxicity. Chem Res Toxicol. 2010;23:1714–25.  https://doi.org/10.1021/tx100186t.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Osaki F, Goto T, Lee SH, Oe T. Predicted multiple selected reaction monitoring to screen activated drug-mediated modifications on human serum albumin. Anal Biochem. 2014;449:59–67.  https://doi.org/10.1016/j.ab.2013.12.016.CrossRefPubMedGoogle Scholar
  23. 23.
    Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–7.  https://doi.org/10.1016/0003-9861(59)90090-6.CrossRefPubMedGoogle Scholar
  24. 24.
    Miyagi M, Wan Q, Ahmad MF, Gokulrangan G, Tomechko SE, Bennett B, et al. Histidine hydrogen-deuterium exchange mass spectrometry for probing the microenvironment of histidine residues in dihydrofolate reductase. PLoS One. 2011;6:e17055.  https://doi.org/10.1371/journal.pone.0017055.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Casasnovas R, Adrover M, Ortega-Castro J, Frau J, Donoso J, Muñoz F. C–H activation in pyridoxal-5′-phosphate Schiff bases: the role of the imine nitrogen. A combined experimental and computational study. J Phys Chem B. 2012;116:10665–−10675.  https://doi.org/10.1021/jp303678n.CrossRefPubMedGoogle Scholar
  26. 26.
    Zoltewicz JA, Clark DF, Sharpless TW, Grabe G. Kinetics and mechanism of the acid-catalyzed hydrolysis of some purine nucleosides. J Am Chem Soc. 1970;92:1741–−1749.  https://doi.org/10.1021/ja00709a055.CrossRefPubMedGoogle Scholar
  27. 27.
    Oe T, Lee SH, Silva Elipe MV, Arison BH, Blair IA. A novel lipid hydroperoxide-derived modification to arginine. Chem Res Toxicol. 2003;16:1598–605.  https://doi.org/10.1021/tx034178l.CrossRefPubMedGoogle Scholar
  28. 28.
    Rindgen D, Nakajima M, Wehrli S, Xu K, Blair IA. Covalent modifications to 2′-deoxyguanosine by 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chem Res Toxicol. 1999;12:1195–204.  https://doi.org/10.1021/tx990034o.CrossRefPubMedGoogle Scholar
  29. 29.
    Trostchansky A, Lind S, Hodara R, Oe T, Blair IA, Ischiropoulos H, et al. Interaction with phospholipids modulates alpha-synuclein nitration and lipid–protein adduct formation. Biochem J. 2006;393:343–9.  https://doi.org/10.1042/BJ20051277.CrossRefPubMedGoogle Scholar
  30. 30.
    Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science. 2001;292:2083–6.  https://doi.org/10.1126/science.1059501.CrossRefPubMedGoogle Scholar
  31. 31.
    Oe T, Arora JS, Lee SH, Blair IA. A novel lipid hydroperoxide-derived cyclic covalent modification to histone H4. J Biol Chem. 2003;278:42098–105.  https://doi.org/10.1074/jbc.M308167200.CrossRefPubMedGoogle Scholar
  32. 32.
    Jian W, Lee SH, Mesaros C, Oe T, Elipe MV, Blair IA. A novel 4-oxo-2(E)-nonenal-derived endogenous thiadiazabicyclo glutathione adduct formed during cellular oxidative stress. Chem Res Toxicol. 2007;20:1008–18.  https://doi.org/10.1021/tx700001t.CrossRefPubMedGoogle Scholar
  33. 33.
    Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, et al. Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug Metab Dispos. 2011;39:1247–54.  https://doi.org/10.1124/dmd.111.039180.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos. 2002;30:314–8.  https://doi.org/10.1124/dmd.30.3.314.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang H, Lau WC, Hollenberg PF. Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes. Mol Pharmacol. 2012;82:302–9.  https://doi.org/10.1124/mol.112.079061.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos. 2003;31:1499–506.  https://doi.org/10.1124/dmd.31.12.1499.CrossRefPubMedGoogle Scholar
  37. 37.
    Rousu T, Tolonen A. Characterization of cyanide-trapped methylated metabonates formed during reactive drug metabolite screening in vitro. Rapid Commun Mass Spectrom. 2011;25:1382–90.  https://doi.org/10.1002/rcm.5005.CrossRefPubMedGoogle Scholar
  38. 38.
    Harrison AC, Kitteringham NR, Clarke JB, Park BK. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol. 1992;43:1421–30.  https://doi.org/10.1016/0006-2952(92)90198-R.CrossRefPubMedGoogle Scholar
  39. 39.
    McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol. 2007;20:1833–42.  https://doi.org/10.1021/tx7001228.CrossRefPubMedGoogle Scholar
  40. 40.
    Lassila T, Mattila S, Turpeinen M, Tolonen A. Glutathione trapping of reactive drug metabolites produced by biomimetic metalloporphyrin catalysts. Rapid Commun Mass Spectrom. 2015;29:521–32.  https://doi.org/10.1002/rcm.7129.CrossRefPubMedGoogle Scholar
  41. 41.
    Yu LJ, Chen Y, DeNinno MP, O’Connell TN, Hop CECA. Identification of a novel glutathione adduct of diclofenac, 4′-hydroxy-2′-glutathion-deschloro-diclofenac, upon incubation with human liver microsomes. Drug Metab Dispos. 2005;33:484–8.  https://doi.org/10.1124/dmd.104.002840.CrossRefPubMedGoogle Scholar
  42. 42.
    Kent UM, Lin H, Mills DE, Regal KA, Hollenberg PF. Identification of 17-α-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol. 2006;19:279–87.  https://doi.org/10.1021/tx050256o.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kang P, Dalvie D, Smith E, Zhou S, Deese A. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007;35:1081–8.  https://doi.org/10.1124/dmd.107.014860.CrossRefPubMedGoogle Scholar
  44. 44.
    Williams DP, Antoine DJ, Butler PJ, Jones R, Randle L, Payne A, et al. The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore. J Pharmacol Exp Ther. 2007;322:1208–20.  https://doi.org/10.1124/jpet.107.125302.CrossRefPubMedGoogle Scholar
  45. 45.
    Zhang H, Yang Y. An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. J Mass Spectrom. 2008;43:1181–90.  https://doi.org/10.1002/jms.1390.CrossRefPubMedGoogle Scholar
  46. 46.
    Ju C, Uetrecht JP. Oxidation of a metabolite of indomethacin (desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab Dispos. 1998;26:676–680. doi: not available (http://dmd.aspetjournals.org/content/dmd/26/7/676.full.pdf).
  47. 47.
    Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos. 2009;37:1557–62.  https://doi.org/10.1124/dmd.108.024851.CrossRefPubMedGoogle Scholar
  48. 48.
    Gardner I, Zahid N, Maccrimmon D, Uetrecht JP. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol. 1998;53:991–998. doi: not available (http://molpharm.aspetjournals.org/content/molpharm/53/6/991.full.pdf).
  49. 49.
    Baughman TM, Graham RA, Wells-Knecht K, Silver IS, Tyler LO, Wells-Knecht M, et al. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2005;33:733–8.  https://doi.org/10.1124/dmd.104.002683.CrossRefPubMedGoogle Scholar
  50. 50.
    Uetrecht JP. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther. 1985;232:420–425. doi: not available (http://jpet.aspetjournals.org/content/232/2/420).
  51. 51.
    Sasame HA, Liberato DJ, Gillette JA. The formation of a glutathione conjugate derived from propranolol. Drug Metab Dispos. 1987;15:349–355. doi: not available (http://dmd.aspetjournals.org/content/dmd/15/3/349.full.pdf).
  52. 52.
    Alvarez-Sánchez R, Montavon F, Hartung T, Pähler A. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem Res Toxicol. 2006;19:1106–16.  https://doi.org/10.1021/tx050353h.CrossRefPubMedGoogle Scholar
  53. 53.
    Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos. 1991;19:900–906. doi: not available (http://dmd.aspetjournals.org/content/dmd/19/5/900.full.pdf).
  54. 54.
    Shimizu S, Atsumi R, Nakazawa T, Fujimaki Y, Sudo K, Okazaki O. Metabolism of ticlopidine in rats: identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide. Drug Metab Dispos. 2009;37:1904–15.  https://doi.org/10.1124/dmd.109.027524.CrossRefPubMedGoogle Scholar
  55. 55.
    Nishiya T, Kato M, Suzuki T, Maru C, Kataoka H, Hattori C, et al. Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Toxicol Lett. 2008;183:81–9.  https://doi.org/10.1016/j.toxlet.2008.10.009.CrossRefPubMedGoogle Scholar
  56. 56.
    Chen Q, Doss GA, Tung EC, Liu W, Tang YS, Braun MP, et al. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos. 2006;34:145–51.  https://doi.org/10.1124/dmd.105.004341.CrossRefPubMedGoogle Scholar
  57. 57.
    McConn IIDJ, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos. 2004;32:1083–91.  https://doi.org/10.1124/dmd.32.10.1083.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Shuto Hosaka
    • 1
    • 2
  • Takuto Honda
    • 1
    • 3
  • Seon Hwa Lee
    • 1
  • Tomoyuki Oe
    • 1
  1. 1.Department of Bio-analytical Chemistry, Graduate School of Pharmaceutical SciencesTohoku UniversitySendaiJapan
  2. 2.Forensic Science LaboratoryNiigata Prefectural Police H.Q.NiigataJapan
  3. 3.Eli Lilly Japan K.KKobeJapan

Personalised recommendations